Unilateral Thoracic Erythema with Induration

Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. Cancer J Clin 2006; 56 (2): 106–30 Lookingbill DP, Spangler N, Sexton FM. Skin involvement as the presenting sign of internal carcinoma: a retrospective study of 7316 cancer patients. J Am Acad Dermatol 1990; 22 (1): 19–26 Brownstein MH, Helwig EB. Metastatic tumors of the skin. Cancer 1972; 29 (5): 1298–307 Schwartz RA. Cutaneous metastatic disease. J Am Acad Dermatol 1995; 33 (2 Pt 1): 161–82 Lucas FV, Perez-Mesa C. Inflammatory carcinoma of the breast. Cancer 1978; 41 (4): 1595–605 Cristofanilli M, Buzdar AU, Hortobagyi GN. Update on the management of inflammatory breast cancer. Oncologist 2003; 8 (2): 141–8 Cox SE, Cruz Jr PD. A spectrum of inflammatory metastasis to skin via lymphatics: three cases of carcinoma erysipeloides. J Am Acad Dermatol 1994; 30 (2 Pt 2): 304–7 Lever LR, Holt PJ. Carcinoma erysipeloides. Br J Dermatol 1991; 124 (3): 279–82 Krumbholz A, Heinemann C, Elsner P, et al. Erythematous swelling of the left arm in a 70-year old woman: erysipelas carcinomatosum in breast carcinoma [in German]. J Dtsch Dermatol Ges 2006; 4 (1): 69–71 Ellis DL, Teitelbaum SL. Inflammatory carcinoma of the breast: a pathologic definition. Cancer 1974; 33 (4): 1045–7 Singletary SE, Connolly JL. Breast cancer staging: working with the sixth edition of the AJCC Cancer Staging Manual. CA Cancer J Clin 2006; 56 (1): 37–47 Radunsky GS, van Golen KL. The current understanding of the molecular determinants of inflammatory breast cancer metastasis. Clin Exp Metastasis 2005; 22 (8): 615–20 Van den Eynden GG, Van der Auwera I, Van Laere S, et al. Validation of a tissue microarray to study differential protein expression in inflammatory and non-inflammatory breast cancer. Breast Cancer Res Treat 2004; 85 (1): 13–22 Wu M, Wu ZF, Kumha-Sinha C, et al. RhoC induces differential expression of genes involved in invasion and metastasis in MCF10A breast cells. Breast Cancer Res Treat 2004; 84 (1): 3–12 Gage I, Schnitt SJ, Recht A, et al. Skin recurrences after breast-conserving therapy for early-stage breast cancer. J Clin Oncol 1998; 16 (2): 480–6 Kurtz JM, Jacquemier J, Brandone H, et al. Inoperable recurrence after breast-conserving surgical treatment and radiotherapy. Surg Gynecol Obstet 1991; 172 (5): 357–61 Taylor G, Meltzer A. Inflammatory carcinoma of the breast. Am J Cancer 1938; 33: 33–49 Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: a review. J Clin Oncol 1992; 10 (6): 1014–24 Kao J, Conzen SD, Jaskowiak NT, et al. Concomitant radiation therapy and paclitaxel for unresectable locally advanced breast cancer: results from two consecutive phase I/II trials. Int J Radiat Oncol Biol Phys 2005; 61 (4): 1045–53 Hennessy BT, Gonzalez-Angulo AM, Hortobagyi GN, et al. Disease-free and overall survival after pathologic complete disease remission of cytologically proven inflammatory breast carcinoma axillary lymph node metastases after primary systemic chemotherapy. Cancer 2006; 106 (5): 1000–6 Lerebours F, Bieche I, Lidereau R. Update on inflammatory breast cancer. Breast Cancer Res 2005; 7 (2): 52–8 Nomura M, Inoue Y, Fujita S, et al. Pathological complete response to trastuzumab and paclitaxel in a patient with inflammatory local recurrence following breast conserving surgery. Breast Cancer 2005; 12 (3): 226–30 Okawa Y, Sugiyama K, Aiba K, et al. Successful combination therapy with trastuzumab and paclitaxel for adriamycin and docetaxel-resistant inflammatory breast cancer. Breast Cancer 2004; 11 (3): 309–12 Spector NL, Blackwell K, Hurley J, et al. EGF103009, a phase II trial of lapatinib monotherapy in patients with relapsed/refractory inflammatory breast cancer (IBC): clinical activity and biologic predictors of response. Proceedings of the 42nd annual meeting of the American Society of Clinical Oncology; 2006 Jun 2-6; Atlanta (GA)